Figure 5From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study Trough blood concentrations of vinorelbine over time. Scatter plots of serial trough concentrations of VLR and its active metabolite DVLR over time in a patient prostate cancer patient treated at 50 mg dose arm (A) and a breast cancer patient treated at 40 mg (B) and median (plus SEM) values of steady state levels of all patients treated at the three dose arms (C).Back to article page